All type of patients: 2 trials - CLEOPATRA - neoSphere (Group B)
| pertuzumab + trastuzumab +docetaxel vs trastuzumab + docetaxel | No demonstrated result suggested death (overall survival) by 32% (not demonstrated) suggested progression or death (progression free survival PFS) by 38% (not demonstrated) |
HER2 positive patients: 1 trials - Aphinity
| pertuzumab vs placebo | No demonstrated result |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
